403 related articles for article (PubMed ID: 36899928)
1. Bile Acids and Biliary Fibrosis.
Aseem SO; Hylemon PB; Zhou H
Cells; 2023 Mar; 12(5):. PubMed ID: 36899928
[TBL] [Abstract][Full Text] [Related]
2. The gut-liver axis in cholangiopathies: focus on bile acid based pharmacological treatment.
Cariello M; Gadaleta RM; Moschetta A
Curr Opin Gastroenterol; 2022 Mar; 38(2):136-143. PubMed ID: 35034082
[TBL] [Abstract][Full Text] [Related]
3. Bile acid receptors in the biliary tree: TGR5 in physiology and disease.
Deutschmann K; Reich M; Klindt C; Dröge C; Spomer L; Häussinger D; Keitel V
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1319-1325. PubMed ID: 28844960
[TBL] [Abstract][Full Text] [Related]
4. Animal models of cholestasis: An update on inflammatory cholangiopathies.
Mariotti V; Cadamuro M; Spirli C; Fiorotto R; Strazzabosco M; Fabris L
Biochim Biophys Acta Mol Basis Dis; 2019 May; 1865(5):954-964. PubMed ID: 30398152
[TBL] [Abstract][Full Text] [Related]
5. Macrophages in cholangiopathies.
Bruneau A; Guillot A; Tacke F
Curr Opin Gastroenterol; 2022 Mar; 38(2):114-120. PubMed ID: 35098932
[TBL] [Abstract][Full Text] [Related]
6. Cellular Interactions and Crosstalk Facilitating Biliary Fibrosis in Cholestasis.
Ceci L; Gaudio E; Kennedy L
Cell Mol Gastroenterol Hepatol; 2024; 17(4):553-565. PubMed ID: 38216052
[TBL] [Abstract][Full Text] [Related]
7. Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis.
Pollheimer MJ; Racedo S; Mikels-Vigdal A; Marshall D; Bowlus C; Lackner C; Madl T; Karlsen TH; Hov JR; Lyman SK; Adamkewicz J; Smith V; Moreau E; Zollner G; Eide TJ; Stojakovic T; Scharnagl H; Gruber HJ; Stauber RE; Trauner M; Fickert P
J Hepatol; 2018 Aug; 69(2):368-377. PubMed ID: 29709678
[TBL] [Abstract][Full Text] [Related]
8. Chronic cholestatic liver diseases: clues from histopathology for pathogenesis.
Pollheimer MJ; Fickert P; Stieger B
Mol Aspects Med; 2014 Jun; 37():35-56. PubMed ID: 24141039
[TBL] [Abstract][Full Text] [Related]
9. Cellular senescence in the cholangiopathies: a driver of immunopathology and a novel therapeutic target.
Trussoni CE; O'Hara SP; LaRusso NF
Semin Immunopathol; 2022 Jul; 44(4):527-544. PubMed ID: 35178659
[TBL] [Abstract][Full Text] [Related]
10. Selected Aspects of the Intricate Background of Immune-Related Cholangiopathies-A Critical Overview.
Kasztelan-Szczerbinska B; Rycyk-Bojarzynska A; Szczerbinska A; Cichoz-Lach H
Nutrients; 2023 Feb; 15(3):. PubMed ID: 36771465
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies.
Trauner M; Halilbasic E; Kazemi-Shirazi L; Kienbacher C; Staufer K; Traussnigg S; Hofer H
Dig Dis; 2014; 32(5):631-6. PubMed ID: 25034298
[TBL] [Abstract][Full Text] [Related]
12. Cellular senescence in the cholangiopathies.
Bogert PS; O'Hara SP; LaRusso NF
Curr Opin Gastroenterol; 2022 Mar; 38(2):121-127. PubMed ID: 35098933
[TBL] [Abstract][Full Text] [Related]
13. Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases.
Li Y; Tang R; Leung PSC; Gershwin ME; Ma X
Autoimmun Rev; 2017 Sep; 16(9):885-896. PubMed ID: 28698093
[TBL] [Abstract][Full Text] [Related]
14. The Cholangiopathies.
Lazaridis KN; LaRusso NF
Mayo Clin Proc; 2015 Jun; 90(6):791-800. PubMed ID: 25957621
[TBL] [Abstract][Full Text] [Related]
15. Immune-mediated cholangiopathies in children: the need to better understand the pathophysiology for finding the future possible treatment targets.
Grama A; Mititelu A; Sîrbe C; Benţa G; Pop TL
Front Immunol; 2023; 14():1206025. PubMed ID: 37928553
[TBL] [Abstract][Full Text] [Related]
16. Targeting bile salt homeostasis in biliary diseases.
Trampert DC; Kunst RF; van de Graaf SFJ
Curr Opin Gastroenterol; 2024 Mar; 40(2):62-69. PubMed ID: 38230695
[TBL] [Abstract][Full Text] [Related]
17. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
Trauner M; Fickert P; Halilbasic E; Moustafa T
Wien Med Wochenschr; 2008; 158(19-20):542-8. PubMed ID: 18998069
[TBL] [Abstract][Full Text] [Related]
18. Secretin alleviates biliary and liver injury during late-stage primary biliary cholangitis via restoration of secretory processes.
Kennedy L; Carpino G; Owen T; Ceci L; Kundu D; Meadows V; Kyritsi K; Franchitto A; Onori P; Isidan A; Zhang W; Ekser B; Alvaro D; Gaudio E; Gershwin ME; Francis H; Glaser S; Alpini G
J Hepatol; 2023 Jan; 78(1):99-113. PubMed ID: 35987275
[TBL] [Abstract][Full Text] [Related]
19. Cholangiocyte-Derived Exosomal Long Noncoding RNA H19 Promotes Hepatic Stellate Cell Activation and Cholestatic Liver Fibrosis.
Liu R; Li X; Zhu W; Wang Y; Zhao D; Wang X; Gurley EC; Liang G; Chen W; Lai G; Pandak WM; Robert Lippman H; Bajaj JS; Hylemon PB; Zhou H
Hepatology; 2019 Oct; 70(4):1317-1335. PubMed ID: 30985008
[TBL] [Abstract][Full Text] [Related]
20. New insights into the pathogenesis of primary biliary cholangitis asymptomatic stage.
Reshetnyak VI; Maev IV
World J Gastroenterol; 2023 Oct; 29(37):5292-5304. PubMed ID: 37899787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
